Insight Molecular to amend merger agreement

Insight Molecular Diagnostics Inc. amended its merger agreement with equityholder David MacKenzie to modify Earnout Consideration terms, specifically exceeding a minimum cash payout. The amendment's market relevance lies in materially altering the financial outcomes associated with the ongoing corporate merger.